Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics by André, F, Stemmer, S.M, Hortobagyi, G.N, Burris, H.A, Paluch-Shimon, S, Campone, M, Villanueva, C, Chan, A, Wist, E, Marschner, N, Bachelot, T, Blau, S, Janni, W, Verma, S, Conte, P, Dhuria, S, Yang, S, Stegert, M, Germa, C, Arteaga, C.L

Get full text

First-line ribociclib + letrozole in patients with HR+, HER2–advanced breast cancer (ABC) who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 trial by Conte, P, Paluch-Shimon, S, Burris, H.A, Petrakova, K, Blackwell, K.L, Dittrich, C, Arteaga, C.L, Sutradhar, S, Miller, M, Campone, M

Get full text

193 Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC) by Saura, C, Burris, H, Arteaga, C.L, Mayer, I, Germa, C, Fretault, N, Sternberg, D, Trandafir, L, Massacesi, C, Rodon, J

Get full text

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer by Dillon, L M, Bean, J R, Yang, W, Shee, K, Symonds, L K, Balko, J M, McDonald, W H, Liu, S, Gonzalez-Angulo, A M, Mills, G B, Arteaga, C L, Miller, T W

Get full text

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A by Reckamp, K., Song, Z., Gettinger, S., Mitchell, E.P., Wright, J.J., Moscow, J.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V by Gien, L., Song, Z., Poklepovic, A., Collisson, E.A., Mitchell, E.P., Zweibel, J.A., Harris, P., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

144 Reduced expression of HER3 with a specific RNA antagonist is associated with antitumor effects in preclinical models of cancer by Wu, Y, Muraoka-Cook, R.S, Zhang, Y, Greenberger, L.M, Rinehart, C, Arteaga, C.L, Horak, I.D

Get full text

and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling by Cheng, H, Liu, P, Ohlson, C, Xu, E, Symonds, L, Isabella, A, Muller, W.J, Lin, N.U, Krop, I.E, Roberts, T.M, Winer, E.P, Arteaga, C.L, Zhao, J.J

Get full text

12LBA - Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics by André, F., Stemmer, S.M., Hortobagyi, G.N., Burris, H.A., Paluch-Shimon, S., Campone, M., Villanueva, C., Chan, A., Wist, E., Marschner, N., Bachelot, T., Blau, S., Janni, W., Verma, S., Conte, P., Dhuria, S., Yang, S., Stegert, M., Germa, C., Arteaga, C.L.

Get full text

P141 - First-line ribociclib + letrozole in patients with HR+, HER2–advanced breast cancer (ABC) who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 tr... by Conte, P., Paluch-Shimon, S., Burris, H.A., Petrakova, K., Blackwell, K.L., Dittrich, C., Arteaga, C.L., Sutradhar, S., Miller, M., Campone, M.

Get full text

Click chemistry for [99mTc(CO)3] labeling of Lys3-bombesin by Ferro-Flores, G., Rivero, I.A., Santos-Cuevas, C.L., Sarmiento, J.I., Arteaga de Murphy, C., Ocampo-García, B.E., García-Becerra, R., Ordaz-Rosado, D.

Get full text

Click chemistry for [ 99mTc(CO) 3] labeling of Lys 3-bombesin by Ferro-Flores, G., Rivero, I.A., Santos-Cuevas, C.L., Sarmiento, J.I., Arteaga de Murphy, C., Ocampo-García, B.E., García-Becerra, R., Ordaz-Rosado, D.

Get full text